Translating sequencing-based tumour profiling and prediction models to the clinic
DNA and RNA sequencing are now standard tools in cancer research but are not yet widely implemented in the clinical setting. Translation of sequencing-based molecular phenotyping to the clinic holds the promise to provide a quantitative and more detailed basis for diagnosis and prognosis compared to conventional pathology, and thus lead to improved patient outcomes.
In this talk I will present results from the ClinSeq (Clinical Sequencing of Cancer in Sweden) breast cancer study. ClinSeq aims to develop and evaluate infrastructure, bioinformatic methods and statistical models to bring sequencing-based cancer diagnostics to the clinic. Using multivariate prediction modelling we assess to what extent DNA and RNA sequencing-based molecular profiling of primary breast cancer tumours can replace, and potentially augment, current routine pathology, including immunohistochemical markers and histological grade. Our results, based on a retrospective study including DNA and RNA sequencing of ~300 primary breast cancer tumours, indicate a high degree of concordance between conventional markers and predictions from models based on sequencing data, while also providing additional treatment relevant information. Around 8% of cases are reclassified by sequencing-based models and these cases also have an increased probability of reclassification under pathological re-examination.
Date:
16 April 2015, 14:00 (Thursday, -1st week, Trinity 2015)
Venue:
Old Road Campus Research Building, Headington OX3 7DQ
Venue Details:
Room 71abc
Speaker:
Dr Mattias Rantalainen (Karolinska Institutet)
Organising department:
Department of Oncology
Organisers:
Anastasia Samsonova (University of Oxford),
Christopher Yau (University of Oxford)
Organiser contact email address:
cyau@well.ox.ac.uk
Host:
Christopher Yau (University of Oxford)
Part of:
Cancer Bioinformatics Seminar Series
Topics:
Booking required?:
Not required
Audience:
Members of the University only
Editor:
Christopher Yau
